Dogecoin Cash, Inc. Releases 2025 Annual Report: Key Financial and Strategic Updates for Investors

Overview

Dogecoin Cash, Inc. has published its Form 10-K for the fiscal year ended December 31, 2025. This detailed report provides insight into the company’s financial performance, capital structure, management, and operational outlook. Investors should closely review the following highlights and critical disclosures, as these may impact the share value and future prospects of the company.

Key Financial Highlights

• Revenue: The company reported revenues of \$738,907 for 2025, a slight decrease compared to 2024. Gross profit margin remained robust at 64% of sales.
• Net Loss: Dogecoin Cash, Inc. incurred a net loss of \$10,043,831 in 2025, up significantly from \$1,780,240 in 2024. Accumulated deficit stood at \$84,389,964 as of year-end 2025.
• Cash Position: The company ended 2025 with \$29,553 in cash, down from \$34,934 in 2024. Cash used in operating activities was \$39,583, with financing activities providing \$34,202.
• Stockholders’ Deficit: Total stockholders’ deficit increased to (\$1,868,567) in 2025 from (\$1,438,844) in 2024, and including non-controlling interest, the total deficit was (\$29,035) in 2025.
• Market Capitalization: The aggregate market value of voting and non-voting common stock held by non-affiliates was approximately \$2,617,808 as of June 30, 2025.
• Shares Outstanding: As of February 28, 2026, 160,109,031 shares of common stock were outstanding, with 71 holders of record.
• Dividend Policy: The company has not declared or paid cash dividends and does not anticipate doing so in the foreseeable future, opting to retain earnings for business development.

Strategic and Operational Developments

• Business Model: Dogecoin Cash, Inc. operates a telemedicine platform, relying on information technology and third-party service providers. Administrative functions are largely conducted remotely.
• Cybersecurity: Management maintains processes to identify and manage cybersecurity risks. As of the report date, no material cybersecurity incidents have affected operations.
• Legal Proceedings: The company is not currently a party to any material legal proceedings.
• Liquidity: The company has historically funded operations through telemedicine revenues and financing transactions. The report indicates a need for additional capital to support future expansion, with potential dilution to current shareholders if equity or convertible debt is raised.
• Controls and Procedures: Management evaluated the effectiveness of disclosure controls and procedures and concluded they were effective as of year-end.

Management and Corporate Governance

• Directors and Officers: The CEO and principal financial officer is David M. Tobias, who holds 25,530,049 shares (15.9% of outstanding shares). Catherine Carroll also serves as an executive officer and director.
• Audit Committee: The Board oversees accounting, financial reporting, and audit processes but has not determined that any member qualifies as an “audit committee financial expert.” The company intends to appoint additional independent directors as it grows.
• Code of Ethics: A Code of Ethics is in place for directors, officers, and employees, with amendments or waivers to be disclosed as required.
• Executive Compensation: Compensation may be paid in cash, equity, or promissory notes and is subject to the company’s financial condition.

Shareholder and Price-Sensitive Considerations

• Significant Losses and Accumulated Deficit: The substantial increase in net loss and accumulated deficit raises concerns about ongoing viability and future capital requirements.
• Capital Raising: The company’s intention to raise capital through public or private placements may lead to dilution of existing shareholders and could impact share price.
• No Dividends: Investors seeking income should note the absence of dividends, as the company intends to reinvest earnings.
• Going Concern: The financial statements have been prepared assuming the company will continue as a going concern, but ongoing losses and deficit suggest risks if capital cannot be raised.
• Control and Ownership: Management and insiders hold significant shares, which could influence governance and strategic direction.

Financial Statements and Auditor’s Opinion

The independent registered public accounting firm delivered an unqualified opinion, confirming the financial statements fairly present the company’s position in accordance with U.S. GAAP. No critical audit matters were identified. Internal controls over financial reporting were also deemed effective, with no material weaknesses noted.

Other Disclosures

• Issuer Purchases: No shares were repurchased during 2025.
• Legal and Regulatory: The company is not a shell company, is not involved in mine safety disclosures, and has submitted all required interactive data files to the SEC.
• Exhibits: Certifications from executive officers regarding Sarbanes-Oxley compliance are included.

Conclusion

Dogecoin Cash, Inc.’s 2025 Annual Report reveals significant operational losses, a growing deficit, and a clear need for additional capital. Investors should monitor the company’s capital raising efforts, as these may dilute ownership and affect share value. The telemedicine platform remains the primary revenue source, but expansion and sustainability depend on successful financing and management execution. No material legal or cybersecurity issues were reported, and controls and governance remain in place, though the lack of a financial expert on the audit committee and the need for independent directors are noted.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should perform their own due diligence and consult with financial advisors before making investment decisions. The information is based on Dogecoin Cash, Inc.’s 2025 Form 10-K and may be subject to change or further updates.

View Dogecoin Cash, Inc. Historical chart here